With Shrinking Market Share, GSK Sells Augmentin, Amoxil U.S. Rights To Dr. Reddy's, Along With Tennessee Manufacturing Site
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Acting on the strategy of hiving off late-stage brands and non-core assets, GlaxoSmithKline Pharma has sold its once marquee anti-bacterial Augmentin and Amoxil brand rights in the U.S. to India's Dr. Reddy's Labs for an undisclosed sum